A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy.

96Background: Treatment with anti-PD1/anti-PDL1 agents is associated with toxicity termed immune related adverse events (iRAEs). While the prevalence of Grade 2 and higher iRAEs is approximately 25...